Objective: To study the spectrum of computed tomographic (CT) morphologies of intracranial tuberculomas and to show the role of CT in evaluating the response to medical management. Subjects and Methods: The case files and CT scans of 20 patients with proven intracranial tuberculomas over a period of 15 years (1985–1999) were reviewed retrospectively. All the patients had pre- and post-contrast axial CT scans of the brain. Follow-up CT studies were done 2–12 months after starting antituberculous chemotherapy (ATT). Results: There were 15 males and 5 females. Single lesions were seen in 65% of patients. The majority of the lesions (78%) were in the frontal and parietal lobes. Rare sites of presentation included midbrain and basal ganglia. The lesions were isodense in 81% of the precontrast studies and all were enhanced after intravenous administration of the contrast medium. Severe mass effect, hydrocephalus and meningeal enhancement were not common findings. In 80% of the patients the follow-up CT scans showed evidence of response to ATT. Conclusion: CT is a reliable modality in the diagnostic workup and follow-up of patients with intracranial tuberculomas. Administration of contrast medium is mandatory for the evaluation of such patients.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.